Skip to main content

Table 1 Patient and study characteristics

From: The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review

Author, year Number of patients Target population Inclusion criteria Prospective or retrospective? Reference standard Mean disease duration at 1st scan (y ± SD) Mean age at imaging (y ± SD) Mean Hoehn and Yahr score Mean UPDRS motor score at imaging (OFF state, 0 to 108) Mean follow-up between scans (y + SD) Radiotracer SPECT judged visually, template or drawn Drug stopped appropriate before SPECT? SPECT judged blindly for results of reference standard?
Chouker, 2001 [20] 8 Clinical PD Step 1 + 2 UKPDS criteria + response to dopaminomimetics Prospective 2nd DAT SPECT 3.6¥, 1 to 6* 57.0, 40 to 76* 2.0 ± 0.8 - 2.0 IPT Template Unclear Unclear
Marek, 2001 [22] 32 Clinical PD Step 1 + 2 UKPDS criteria Prospective 2nd DAT SPECT 2.5¥ ± 2.4 60.0 ± 11.7 1.8 ± 0.7 18.2 ± 8.7 2.3 ± 0.9 Beta Drawn Unclear Yes
Pirker, 2002 [23] 36 Clinical PD Step 1 + 2 UKPDS criteria Prospective 2nd DAT SPECT 4.7¥ ± 2.9 60.0 ± 11.0 2.1 ± 0.4 - 2.2 ± 0.3 Beta Drawn Yes Yes
Marshall, 2009 [49] 99 Clinically uncertain parkinsonism Step 1 UKPDS criteria Prospective 2nd DAT SPECT 2.4ǂ 60.8 ± 4.8 1.5 ± 0.3 9.6 ± 1.3 3.0 fpcit Visual Yes Yes
Isaias, 2010 [48] 13 Clinical PD Steps 1 to 3 UKPDS criteria Prospective 2nd DAT SPECT 5.0¥ ± 2.8 63.4 ± 8.5 - 17.2 ± 6.0 3.2 ± 1.0 fpcit Template Yes Unclear
Perju-Dumbrava, 2012 [46] 8 Pathologically proven PD Neuropathological diagnosis of PD + DAT scan during lifetime Retrospective Pathological evaluation 4.1¥ ± 4.8 68.0 ± 7.2 - - 3.7 ± 3.0ʠ Beta Drawn Unclear Unclear
Colloby, 2012 [47] 12 Pathologically proven PDD PDD according to McKeith criteria + DAT scan during lifetime Retrospective Pathological evaluation 7.9¥ ± 6.3 70.8 ± 4.3 - 35.8 ± 11.9 3.3 ± 1.7ʠ fpcit Template Unclear Unclear
Eggers, 2012 [45] 27 Clinical PD Steps 1 to 3 UKPDS criteria Retrospective 2nd DAT SPECT 3.9¥ 61.7 ± 11.2 - 25.9 ± 5.2 2.5 ± 0.7 fpcit Template Yes Yes
  1. PD, Parkinson’s Disease; SD, standard deviation; UPDRS, Unified Parkinson’s disease rating scale; beta, [123I] β-carboxymethyoxy-3-beta-(4-iodophenyl) tropane; fpcit, [123I]-fluoropropyl-carbomethoxy-3β-4-iodophenyltropane; IPT, 123I-N-(3-iodopropen-2-yl)-2-carbomethoxy-3β-(4-chlorophenyl) tropane; SPECT, single-photon emission computed tomography; CI, confidence interval; PDD, Parkinson’s disease dementia; DAT, dopamine transporter; UKPDS, United Kingdom Parkinson’s Disease society.
  2. *Full range instead of standard deviation.
  3. ¥Disease duration calculated from diagnosis.
  4. ǂDisease duration calculated from first symptoms.
  5. ʠIn this study, the interval is referring to the time between DAT SPECT imaging and pathological evaluation.